Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02115542 · ClinicalTrials.gov registry record · Phase 2
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT02115542 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 39 participants.
The verdict
NCT02115542, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
Interventions
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2014-06-05 |
| Est. Completion | 2021-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02115542
The ClinicalTrials.gov registry entry for NCT02115542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib is the first listed.
NCT02115542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02115542 about?
NCT02115542 is a clinical study titled "Single Agent Regorafenib in Refractory Advanced Biliary Cancers". The main purpose of this study is to see if regorafenib can help control or decrease cancer size in patients with cancer of the bile duct. Researchers also want to find out if regorafenib is safe and tolerable.
What is the current status of trial NCT02115542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2014-06-05. Estimated completion is 2021-09-20.
What interventions are being tested in trial NCT02115542?
The interventions under investigation include: Regorafenib (DRUG).
Who is sponsoring clinical trial NCT02115542?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.